Last updated: May 30, 2026
IOPAMIDOL-300 (typically “iopamidol 300 mg iodine/mL” for intravascular and intrathecal use depending on labeling) sits in the high-volume nonionic iodinated contrast media (ICM) market. The commercial trajectory is shaped by (1) procedure mix in CT angiography and contrast CT, (2) safety and switching dynamics between branded and private-label products, (3) episodic supply constraints in ICM manufacturing, and (4) patent and exclusivity end dates that drive generic erosion and distributor contracting.
How fast is IOPAMIDOL-300 growing and what drives demand in the iodinated contrast market?
Bottom line: Growth is primarily volume-led (imaging utilization and protocol intensity), not pricing-led, with margin pressure from generic and private-label substitution. Demand is concentrated in CT and angiography workflows where throughput and contrast performance matter.
Procedure demand drivers
- CT utilization and protocol expansion: Wider use of contrast-enhanced CT for oncology staging, ED triage, and cardiovascular assessment increases ICM volume per patient.
- Cardiovascular imaging: CT angiography and peripheral angiography drive higher iodine throughput and repeat imaging.
- Hospital outpatient shift: Systems with imaging centers increase purchasing frequency and supply discipline.
- Guideline adherence and formulary standardization: Hospitals standardize ICM products to manage inventory, contrast batching, and nurse workflow.
Competitive substitution dynamics
- Switching is common when clinical equivalence is accepted: Nonionic, low-osmolality ICMs compete on viscosity, osmolality, injection compatibility, and procurement contracts.
- Distributor contracting controls realized pricing: Many systems rationalize SKUs to reduce logistics cost and secure volume discounts.
- Safety and tolerability claims compete, but tend not to sustain premium pricing long-term: Clinical outcomes largely depend on patient risk profile and injection protocol, which compresses long-run pricing power.
What is the revenue exposure for IOPAMIDOL-300 under branded versus generic/pricing erosion scenarios?
Bottom line: Revenue exposure is highest in mature geographies where “iopamidol 300” is commoditized. Financial trajectory depends on whether the portfolio is dominated by a branded product with meaningful market share or by contract manufacturing/private label.
Generic erosion mechanics
- Tender-driven purchasing: Hospitals move to lowest effective cost across approved therapeutic equivalents.
- Multiple authorized generics/private label products: Even when “generic” branding is not visible, the functional market is still price-competitive.
- Rebates and contracting: Net price declines faster than list price as contracts renew.
How to frame financial trajectory (practical model)
Use a two-axis view:
- Volume axis: imaging volumes, procedure growth, and market share retention.
- Price axis: net price change driven by contract renewal timing and competitive intensity.
For IOPAMIDOL-300, historical patterns in ICM typically show:
- Net price compression after major supply expansions or after broader generic/authorized generic entries.
- Upside spikes during supply shortages, when constrained manufacturers can capture short-term premium contracts.
How do patent expiry, exclusivity, and Orange Book status affect IOPAMIDOL-300’s commercial runway?
Bottom line: IOPAMIDOL is an older iodine contrast active ingredient; market dynamics are usually governed less by “new” IP blocking and more by the availability of authorized generics, manufacturing capacity, and product-specific formulation or packaging patents.
Key exclusivity and patent pressure points (what typically governs erosion)
- Composition-of-matter and core process patents on older actives typically expire years earlier for legacy ICMs, shifting competition to:
- Manufacturing process patents
- Specific concentration presentations and packaging
- Method-of-use claims tied to injection protocols or indications
- Formulation and stability improvements that may sustain limited differentiation
Orange Book implications for IOPAMIDOL-300 (commercial impact)
Because IOPAMIDOL is established, Orange Book listings usually matter for:
- Whether specific IOPAMIDOL-300 presentations remain tied to active patents for a given holder
- Whether later entrants can be authorized without Paragraph IV challenges
- Whether brand holders extend enforceability through secondary patents
However, a complete, accurate patent-and-Orange Book claim map cannot be produced here without verified listing-level data tied to the exact “IOPAMIDOL-300” product presentation (strength, dosage form, and NDA/ANDA reference), including patent numbers, listed expiration dates, and exclusivity codes.
What formulation, concentration, and packaging patents typically protect IOPAMIDOL-300?
Bottom line: IP protection in legacy ICMs tends to concentrate in secondary patents (process, stability, and packaging) rather than broad composition-of-matter. This can create “product-specific” barriers even when the active ingredient is old.
Common patent categories in iodinated contrast media
- Sterility assurance and aseptic processing methods
- Manufacturing process improvements
- Particle size control and physicochemical parameters that affect stability and injectability
- Stability improvements (shelf-life extension, resistance to degradation, maintenance of iodine concentration)
- Container closure systems and compatibility claims
- Labeling and use instructions that can support method-of-use claims where enforceable
Why formulation IP matters financially
- It delays approval-to-launch for specific presentations and container types.
- It can support premium contracting if fewer equivalents are available during supply stress.
- It can be circumvented through alternative processes and different packaging, depending on claim scope.
Which companies sell IOPAMIDOL-300 and how does the competitive landscape shape price?
Bottom line: The market is populated by branded and non-branded versions of iopamidol 300 alongside multiple authorized generics and private label products. Price is primarily driven by who can reliably supply contract volumes.
Competitive factors that determine realized pricing
- Supply reliability and lead times
- Hospital formulary placement
- Volume rebates and group purchasing organization (GPO) alignment
- Distribution reach for group purchasing and system-level rollouts
- Injection system compatibility (where institutions standardize pumps or workflow)
When does IOPAMIDOL-300 face exclusivity loss and generic entry risk?
Bottom line: For older actives like iopamidol, the generic entry window is often already open; the primary “risk event” for pricing tends to be supply expansions, loss of supply advantage, or specific presentation-level barriers ending.
A precise exclusivity timeline requires presentation-specific Orange Book and patent data for the exact NDA/holder and labeled concentration (IOPAMIDOL-300 strength mapping to “iodine mg/mL” and dosage form). Without that, a date-driven exclusivity forecast would be inaccurate.
What patent litigation or Paragraph IV challenges affect IOPAMIDOL-300?
Bottom line: For legacy contrast agents, large-scale litigation is less frequent than for newer biologics, but specific holders can still face disputes around secondary patents (process or formulation) or method-of-use claims.
A litigation-impact assessment requires:
- Identified patents listed for the relevant NDA(s)
- Published filings tied to Paragraph IV certifications
- Settlement terms (if any)
- Jurisdictional outcomes
A complete, accurate litigation landscape cannot be compiled here without verified court docket and Orange Book patent listing mapping for the exact “IOPAMIDOL-300” product.
How does FDA approval status (NDA vs ANDA) affect market access for IOPAMIDOL-300?
Bottom line: Market access depends on whether products are:
- Brand NDA products with approved labeling that hospitals already buy, or
- ANDA/authorized generic products entering through established compatibility and safety profiles.
What matters for commercial trajectory post-approval
- Whether the entrant gains formulary acceptance
- Whether substitution is allowed by hospital policy
- Whether supply and distribution scale is sufficient to win contracting
- Whether the entrant’s presentation (container type/volume) matches institutional protocols
What supply constraints and manufacturing risks can swing IOPAMIDOL-300 pricing?
Bottom line: ICM markets can experience acute supply mismatches due to:
- constrained aseptic capacity
- batch failures or sterility/QA holds
- container supply disruptions
- specialty raw material availability
Financial mechanism during shortages
- Shortage pricing premiums can appear temporarily through:
- expedited contracting
- emergency procurement
- higher distributor margin capture
- Reversion occurs when manufacturing capacity normalizes.
How does IOPAMIDOL-300 compare with other iodinated contrast media on commercial dynamics?
Bottom line: Competing nonionic low-osmolality ICMs usually trade off on performance and price under contracting pressure. Switching between actives (or within actives via authorized equivalents) can be fast when clinical teams accept interchangeability.
Typical comparison dimensions that influence procurement
- Viscosity at injection temperature (affects patient comfort and injection rate)
- Osmolality and tolerability profiles
- Injection compatibility with existing pump systems
- Shelf-life and packaging match
- Net unit cost after rebates
What is the likely financial trajectory if IOPAMIDOL-300 is in a mature, commoditizing phase?
Bottom line: In a commoditizing phase, trajectory usually shows:
- flat to moderate volume growth with pricing declines
- margin compression unless supply control or differentiated presentation exists
- earnings volatility tied to supply events and contract timing
Net revenue direction drivers
- Positive:
- procedure volume growth
- increased CT penetration and cardiovascular imaging utilization
- Negative:
- net price pressure from authorized generics and private label
- contract renegotiation downward at renewal cycles
- inventory normalization after shortages
Key Takeaways
- IOPAMIDOL-300 demand is primarily volume-led via CT and angiography procedure growth.
- Pricing is usually contract-controlled, with long-run net price erosion from authorized generics and private label.
- Short-term financial upside and downside typically track supply reliability and contract timing, not innovation cycles.
- A precise exclusivity/patent and litigation-driven runway for “IOPAMIDOL-300” cannot be dated accurately without presentation-specific Orange Book and patent listing data tied to the exact NDA/holder and product configuration.
FAQs
- How do hospital formularies decide whether to switch to generic iopamidol 300?
- What inventory and cold-chain steps affect availability and lead time for iopamidol 300 presentations?
- Do container size and packaging format changes impact substitutability for IOPAMIDOL-300 in tenders?
- How do nonionic low-osmolality contrast media differ in procurement pricing beyond list price?
- What supply-chain failure modes most frequently disrupt iodinated contrast media availability and revenue?
References
- FDA Orange Book. “Approved Drug Products with Therapeutic Equivalence Evaluations.” U.S. Food and Drug Administration. https://www.accessdata.fda.gov/scripts/cder/daf/
- FDA Drug Shortages. U.S. Food and Drug Administration. https://www.fda.gov/drugs/drug-shortages
